JP2010526153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526153A5 JP2010526153A5 JP2010507601A JP2010507601A JP2010526153A5 JP 2010526153 A5 JP2010526153 A5 JP 2010526153A5 JP 2010507601 A JP2010507601 A JP 2010507601A JP 2010507601 A JP2010507601 A JP 2010507601A JP 2010526153 A5 JP2010526153 A5 JP 2010526153A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense nucleic
- antibody
- seq
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91629807P | 2007-05-06 | 2007-05-06 | |
| US60/916,298 | 2007-05-06 | ||
| PCT/US2008/062789 WO2008137901A2 (en) | 2007-05-06 | 2008-05-06 | Methods for treating and preventing gi syndrome and graft versus host disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015256345A Division JP6251234B2 (ja) | 2007-05-06 | 2015-12-28 | Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526153A JP2010526153A (ja) | 2010-07-29 |
| JP2010526153A5 true JP2010526153A5 (enExample) | 2011-06-23 |
| JP5924863B2 JP5924863B2 (ja) | 2016-05-25 |
Family
ID=39944232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507601A Active JP5924863B2 (ja) | 2007-05-06 | 2008-05-06 | Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 |
| JP2015256345A Active JP6251234B2 (ja) | 2007-05-06 | 2015-12-28 | Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015256345A Active JP6251234B2 (ja) | 2007-05-06 | 2015-12-28 | Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US8562993B2 (enExample) |
| EP (1) | EP2152287B1 (enExample) |
| JP (2) | JP5924863B2 (enExample) |
| AU (1) | AU2008247368B2 (enExample) |
| CA (1) | CA2686722C (enExample) |
| WO (1) | WO2008137901A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2152287B1 (en) | 2007-05-06 | 2014-04-02 | Sloan Kettering Institute For Cancer Research | Methods for treating and preventing gi syndrome and graft versus host disease |
| US20100255514A1 (en) * | 2007-08-16 | 2010-10-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Tumor cell-derived microvesicles |
| EP2176665B1 (en) | 2007-08-16 | 2016-03-02 | The Royal Institution for the Advancement of Learning / McGill University | Tumor cell-derived microvesicles |
| US20130203081A1 (en) * | 2010-04-13 | 2013-08-08 | Janusz Rak | Tumor cell-derived microvesicles |
| EP2854850B1 (en) * | 2012-05-25 | 2021-05-26 | Sloan Kettering Institute For Cancer Research | Compositions for treating or preventing radiation disease and gi syndrome |
| EP3177650B1 (en) | 2014-08-07 | 2025-11-05 | Memorial Sloan-Kettering Cancer Center | Anti-ceramide antibodies |
| AU2016221305B2 (en) * | 2015-02-18 | 2021-05-27 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP4140492A1 (en) | 2015-04-21 | 2023-03-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| WO2017119988A2 (en) * | 2015-12-10 | 2017-07-13 | Memorial Sloan Kettering Cancer Center | Radioprotection by wnt activation |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP3612211A4 (en) * | 2017-04-17 | 2021-02-17 | Memorial Sloan-Kettering Cancer Center | INTESTINAL PROTECTIVE EFFECT OF RIG-I / MAVS AND STING ACTIVATION |
| WO2020231629A1 (en) * | 2019-05-16 | 2020-11-19 | Snake River Bioscience, Inc. | Compositions and methods for the treatment of major depressive disorder |
| US10975169B1 (en) * | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
| CN112255221A (zh) * | 2020-10-16 | 2021-01-22 | 航科中投生物技术（北京）有限公司 | 一种生物防护过滤介质浓度及喷涂效果的比色鉴定方法 |
| EP4308231A4 (en) * | 2021-03-16 | 2025-01-29 | Memorial Sloan Kettering Cancer Center | IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES |
| EP4313035A4 (en) * | 2021-03-23 | 2025-05-28 | Spinogenix, Inc. | CERTAIN FASCIN-BINDING COMPOUNDS FOR SPINOGENESIS |
| WO2025076313A1 (en) * | 2023-10-04 | 2025-04-10 | Memorial Sloan-Kettering Cancer Center | Combination administration of bone marrow and anti-ceramide antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4950649A (en) | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
| JPH02128697A (ja) * | 1988-11-09 | 1990-05-17 | Hoechst Japan Ltd | 抗フコシルセラミドモノクローナル抗体 |
| US5643602A (en) | 1989-11-22 | 1997-07-01 | Astra Aktiebolag | Oral composition for the treatment of inflammatory bowel disease |
| US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| US5851548A (en) | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
| WO1997037637A1 (en) | 1996-04-04 | 1997-10-16 | Ortho Pharmaceutical Corporation | Liposome-based topical vitamin d formulation |
| WO1998019167A2 (en) * | 1996-10-29 | 1998-05-07 | Fred Hutchinson Cancer Research Center, Inc. | Cell stress regulated human mhc class i gene |
| US20030190715A1 (en) * | 2000-10-12 | 2003-10-09 | Grosse William M. | Novel proteins and nucleic acids encoding same |
| US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
| DE10239531A1 (de) * | 2002-08-23 | 2004-03-04 | Gulbins, Erich, Prof. Dr. | Prophylaxe und Therapie von Infektionserkrankungen |
| WO2005025489A2 (en) | 2003-05-09 | 2005-03-24 | Curagen Corporation | Therapeutic use of g53135-05(fgf-20) in radiation protection |
| KR100565437B1 (ko) | 2003-07-31 | 2006-03-30 | 중앙대학교 산학협력단 | 신규한 스핑고마이엘리나제 효소, 그에 대한 항체, 안티센스 및 제조방법 |
| JP2008546647A (ja) * | 2005-06-08 | 2008-12-25 | デューク ユニバーシティ | 移植のための抗−ｃｄ１９抗体治療 |
| US8383095B2 (en) | 2006-02-14 | 2013-02-26 | Cellerant Therapeutics, Inc. | Methods and compositions for enhancing engraftment of hematopoietic stem cells |
| EP2152287B1 (en) | 2007-05-06 | 2014-04-02 | Sloan Kettering Institute For Cancer Research | Methods for treating and preventing gi syndrome and graft versus host disease |
-
2008
- 2008-05-06 EP EP08755086.9A patent/EP2152287B1/en active Active
- 2008-05-06 JP JP2010507601A patent/JP5924863B2/ja active Active
- 2008-05-06 CA CA2686722A patent/CA2686722C/en active Active
- 2008-05-06 WO PCT/US2008/062789 patent/WO2008137901A2/en not_active Ceased
- 2008-05-06 US US12/599,280 patent/US8562993B2/en active Active
- 2008-05-06 AU AU2008247368A patent/AU2008247368B2/en active Active
-
2013
- 2013-08-23 US US13/974,405 patent/US9592238B2/en active Active
-
2015
- 2015-12-28 JP JP2015256345A patent/JP6251234B2/ja active Active
-
2017
- 2017-02-20 US US15/437,165 patent/US20170273987A1/en not_active Abandoned
-
2018
- 2018-02-27 US US15/906,868 patent/US11207329B2/en active Active
-
2021
- 2021-11-30 US US17/537,786 patent/US12121525B2/en active Active
-
2024
- 2024-09-20 US US18/892,240 patent/US20250325559A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526153A5 (enExample) | ||
| JP2012029693A5 (enExample) | ||
| CN102712695B (zh) | 能够诱导细胞死亡的ror1生物抑制剂 | |
| KR100883078B1 (ko) | 항-ｔｎｆ 항체, 조성물, 방법 및 용도 | |
| CN102596992B (zh) | 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途 | |
| KR20060054174A (ko) | 항-아밀로이드 항체, 조성물, 방법 및 용도 | |
| JP2005512522A (ja) | Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用 | |
| HRP20161450T1 (hr) | Stabilizirana varijanta aktivinskog receptora iib | |
| JP2014169326A5 (enExample) | ||
| KR20100075639A (ko) | 인간 항-아밀로이드 항체, 조성물, 방법 및 용도 | |
| KR20120089346A (ko) | 높은 차단 활성을 갖는 항-Ｃ5ａ 결합 부분 | |
| Tian et al. | Three TNFR-binding domains of PGRN act independently in inhibition of TNFα binding and activity | |
| JP2012518420A5 (enExample) | ||
| JP2010533171A5 (enExample) | ||
| JP2010516290A5 (enExample) | ||
| CN101415439A (zh) | Glp-1激动剂、组合物、方法和用途 | |
| JP2019088329A5 (enExample) | ||
| JP2013107899A5 (enExample) | ||
| JP2015524413A5 (enExample) | ||
| Momcilović et al. | CXCL12 in control of neuroinflammation | |
| Grossman et al. | Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice | |
| JP2008513513A5 (enExample) | ||
| RU2015120365A (ru) | Ингибирующие олигонуклеотиды и их применение | |
| JP7066669B2 (ja) | 炎症性関節疾患の治療方法 | |
| JP2009532326A5 (enExample) |